8 biotech IPO prospects testing investor appetite - pharmavoice.com
Why now
Thesis: Biotech IPO pipeline tests investor risk appetite
Catalyst to watch: IPO pricing and demand outcomes
Main risk: Weak pricing or withdrawn offerings
Why it matters
Biotech IPO pipeline tests risk appetite; outcome depends on pricing and demand not yet known.
Sources
- googlenews · news.google.com · 2026-09-17 13:22 UTC
- googlenews · news.google.com · 2026-09-17 13:22 UTC
- googlenews · news.google.com · 2026-09-17 13:22 UTC